Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

Sophia Genetics

Other names: Sophia Genetics | SOPHiA GENETICS | SOPHiA GENETICS SA | Sophia Genetics SA | Interactive Biosoftware | SOPHiA Genetics | SOPHiA GENETICS, Inc. | SOPHiA GENETICS, Inc | SOPHiA GENETICS Inc. | SOPHiA GENETICS Inc
Related tests:


SOPHiA GENETICS and Agilent partner on comprehensive solution for cancer analysis (SOPHiA GENETICS Press Release)
"SOPHiA GENETICS...is partnering with Agilent to offer a comprehensive solution for cancer analysis...Through the partnership, the SOPHiA DDM Platform will be integrated with Agilent’s new Research Use Only SureSelect Cancer Comprehensive Genomic Profiling (CGP) Assay Kit. This will enable clinical researchers to accurately identify multiple biomarkers, lowering the risk of missing important information in cancer samples. The partnership brings together these two companies’ strengths in analytics and next generation sequencing (NGS) assay development to facilitate novel approaches to cancer research."
Licensing / partnership
University of Arkansas for Medical Sciences will use SOPHiA GENETICS to advance clinical research for blood cancers (SOPHiA GENETICS Press Release)
"SOPHiA GENETICS...announced the University of Arkansas for Medical Sciences (UAMS), based in Little Rock, AR, will use SOPHiA GENETICS’ platform to support their clinical oncology research. Beginning this year, UAMS will implement the SOPHiA DDM™ platform to gain deeper insights into hematologic malignancies."
Licensing / partnership
SOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation Sequencing (Businesswire)
"SOPHiA GENETICS...announced a new partnership with QIAGEN...that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to enhance tumor analysis through next-generation sequencing (NGS). The partnership will allow customers to order QIAseq panels that can be processed through SOPHiA DDM™, a cloud-based platform that analyzes data from various sources to enable entirely new research perspectives. The partnership will initially support somatic variant detection (an alteration in DNA that occurs after birth) using QIAseq Targeted DNA Pro panels for homologous recombination repair (HRR), a special type of biomarker test to find tumors that have certain mutations that may make them sensitive to PARP inhibitors in oncology."
Licensing / partnership
Synergy laboratories taps SOPHiA GENETICS technology for new cancer profiling solution (SOPHiA GENETICS Press Release)
"SOPHiA GENETICS...announced that Synergy Oncology, part of Synergy Laboratories...will use SOPHiA DDM™ to develop a new cancer profiling solution. The combination of technology from Synergy Oncology and SOPHiA GENETICS will expand Synergy’s oncology portfolio while helping to further the U.S. oncology market...Synergy Oncology...will pair SOPHiA DDM™ for Hereditary Cancers Solution with their state-of-the-art laboratory technologies to launch Totality, a comprehensive end-to-end solution for tumor profiling that will benefit cancer research, clinical studies, and patient care."
Licensing / partnership
Sophia Genetics to commercialize MSK-ACCESS clinical liquid biopsy test (Genomeweb)
"Sophia Genetics said...that it has entered into a collaboration with New York's Memorial Sloan Kettering Cancer Center to combine predictive algorithms in a quest to offer new testing and analytical capabilities to cancer researchers and clinicians worldwide...Sophia will help the cancer center commercialize its MSK-ACCESS clinical liquid biopsy assay. Sophia said that the test will be the first circulating tumor DNA panel to be integrated with the company's flagship DDM analytics platform."
Licensing / partnership • Commercial
New data presented at ESGO showcases clinical relevance of SOPHiA DDM Dx HRD solution (Eurekalert)
"SOPHiA GENETICS...debuted new data at the European Society of Gynaecological Oncology (ESGO) Congress as part of a poster (#PA-065) presented by Prof. Alexandre Harlé of the Institut de Cancérologie de Lorraine, France. The results show an evaluation of Homologous Recombination (HRD) detection supported by a deep learning algorithm in a clinical cohort of ovarian cancer patients treated with a PARP inhibitor. The new evaluation data show the clinical utility of the SOPHiA DDM™ Dx HRD Solution for accurate HRD testing."
Clinical data
Sophia Genetics partners with MSK on clinical decision support, Boundless Bio on ecDNA detection (Genomeweb)
"Sophia Genetics said...that it has signed a memorandum of understanding with Memorial Sloan Kettering Cancer Center to collaborate on predictive tumor analysis and clinical decision support...With MSK, Sophia will contribute its CarePath multimodal analysis platform and other predictive algorithms to the New York-based cancer center's precision oncology databases to deliver actionable insights to MSK clinicians. The collaboration also gives Sophia's network of healthcare providers around the world access to the cancer center's proprietary tumor sequencing assays, including MSK-IMPACT."
Licensing / partnership
SOPHiA GENETICS achieves CE-IVD certification using its SOPHiA DDM™ Platform (SOPHiA GENETICS Press Release)
"SOPHiA GENETICS...announced from the ESHG Conference in Vienna that it has achieved CE-IVD certification for the analytical functionality supported by its cloud-based SOPHiA DDM™ Platform, an accessory to diagnostic applications...Powered by the Company’s proprietary deep learning algorithms, the SOPHiA DDM™ Platform supports state-of-art oncology technologies, including five CE-IVD SOPHiA DDM applications, including the newly registered SOPHiA DDM™ Dx Homologous Recombination Deficiency (HRD) Solution and SOPHiA DDM™ Dx RNAtarget Oncology Solution."
European regulatory
SOPHiA DDM Dx RNAtarget Oncology Solution • SOPHiA DDM HRD Solution
SOPHiA GENETICS provides an update on its DEEP-Lung-IV multimodal clinical study at ASCO 2022 (SOPHiA GENETICS Press Release)
"SOPHiA GENETICS...provides an update on its multimodal DEEP-Lung-IV clinical study (NCT04994795) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting...Insights from the DEEP-Lung-IV study will power one of the applications of the CarePath module of the SOPHiA DDMTM platform, offering advanced data visualization, cohorting, and predictive capabilities in a single solution."
Trial status
SOPHiA GENETICS and REALM IDx sign letter of intent to collaborate in accelerating cancer research (SOPHiA GENETICS Press Release)
"SOPHiA GENETICS...and REALM IDx announced today that they signed a letter of intent to collaborate in the co-development of novel genomic applications and commercialization of multi-modal applications. Together, the companies aim to expand next-generation sequencing (NGS) research for cancer care and develop new multi-modal data streams to improve patient outcomes...Assessments can leverage TumorNEXT-HRD, a product of Ambry Genetics, a subsidiary of REALM IDx. SOPHiA GENETICS and REALM IDx also expect to explore the potential for increasing diagnostic insights by combining Ambry Genetics’ Variant Assessment database (AVA) with SOPHiA GENETICS’ SOPHiA DDM (Data-Driven Medicine) platform for HRD detection."
Licensing / partnership
SOPHiA GENETICS HRD Solution adopted in Asia Pacific (SOPHiA GENETICS Press Release)
"SOPHiA GENETICS...today announced that SOFIVA GENOMICS...is the first institution in Asia Pacific to adopt SOPHiA GENETICS’ technology to support HRD testing...SOFIVA GENOMICS has compared the SOPHiA DDM HRD Solution with alternative solutions on hundreds of ovarian cancer samples and has concluded that SOPHiA GENETICS offered analysis technology to simultaneously detect more HRR (Homologous Recombination Repair) genes, including BRCA 1 and BRCA 2."
Licensing / partnership
SOPHiA GENETICS launches new deep learning capabilities to support the detection of homologous recombination deficiencies (SOPHiA GENETICS Press Release)
"SOPHiA GENETICS...announced today the launch of their SOPHiA DDM Homologous Recombination Deficiency (HRD) Solution, opening new doors for cancer research. The application provides a unique approach for molecular cancer testing by combining the identification of HRD-causing mutations with the analysis of HRD-induced genomic instability across the whole genome of tumor samples...SOPHiA GENETICS is collaborating with AstraZeneca, aiming to expand access to in-house HRD testing across European laboratories and institutions."
Licensing / partnership • Launch
First Japanese institution to utilize SOPHiA GENETICS’ Myeloid Plus Solution (SOPHiA GENETICS Press Release)
"SOPHiA GENETICS...announced an agreement with Hiroshima University...in Hiroshima City, Japan, to support their molecular profiling by next-generation sequencing (NGS) in investigating the pathogenic variants causing different blood cancer disorders...With NGS for myeloid testing not widely available in Japan, a group of Hiroshima University researchers tapped the SOPHiA DDM Platform to assist with the clinical utility of NGS tests for myeloid malignancies. Hiroshima University aimed to establish a framework where the NGS-based testing would become a routine part of clinical diagnosis for myeloid neoplasms."
Licensing / partnership
SOPHiA Myeloid Plus Solution